These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 30629620)

  • 1. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
    Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U
    PLoS One; 2019; 14(1):e0210081. PubMed ID: 30629620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
    Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.
    Brandileone MC; Almeida SCG; Minamisava R; Andrade AL
    Vaccine; 2018 May; 36(19):2559-2566. PubMed ID: 29650385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L;
    Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Reis JN; Azevedo J; de Oliveira AML; Menezes APO; Pedrosa M; Dos Santos MS; Ribeiro LC; Freitas HF; Gouveia EL; Teles MB; Carvalho MDG; Reis MG; Nascimento-Carvalho C; Verani JR
    Vaccine; 2024 Jan; 42(3):591-597. PubMed ID: 38184393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Hammitt LL; Etyang AO; Morpeth SC; Ojal J; Mutuku A; Mturi N; Moisi JC; Adetifa IM; Karani A; Akech DO; Otiende M; Bwanaali T; Wafula J; Mataza C; Mumbo E; Tabu C; Knoll MD; Bauni E; Marsh K; Williams TN; Kamau T; Sharif SK; Levine OS; Scott JAG
    Lancet; 2019 May; 393(10186):2146-2154. PubMed ID: 31000194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique.
    Massora S; Lessa FC; Moiane B; Pimenta FC; Mucavele H; Chaúque A; Cossa A; Verani JR; Tembe N; da Gloria Carvalho M; Muñoz-Almagro C; Sigaúque B
    Vaccine; 2019 Dec; 37(51):7470-7477. PubMed ID: 31575493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.
    Choi YH; Andrews N; Miller E
    PLoS Med; 2019 Jul; 16(7):e1002845. PubMed ID: 31269018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
    Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause V; McIntyre P
    Vaccine; 2015 Nov; 33(48):6666-74. PubMed ID: 26519550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
    Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
    Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Euro Surveill; 2017 Mar; 22(10):. PubMed ID: 28300529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
    Peckeu L; van der Ende A; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2021 Jan; 39(2):431-437. PubMed ID: 33243632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.
    Naucler P; Galanis I; Morfeldt E; Darenberg J; Örtqvist Å; Henriques-Normark B
    Clin Infect Dis; 2017 Nov; 65(11):1780-1789. PubMed ID: 29020171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR; Passadore LF; Takagi EH; Fujii CM; Yoshioka CR; Gilio AE; Martinez MB
    Vaccine; 2013 Dec; 31(51):6150-4. PubMed ID: 23747454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.